Effectiveness of a Barcode Medication Administration System in Reducing Preventable Adverse Drug Events in a Neonatal Intensive Care Unit: A Prospective Cohort Study
Objective
Patients are at risk of harm from medication errors. Barcode medication administration (BCMA) systems are recommended to mitigate preventable adverse drug events (ADEs). Our hypothesis was that a BCMA system would reduce preventable ADEs by 45% in a neonatal intensive care unit.
Study design
We conducted a prospective, observational, cohort study of a BCMA system intervention in a neonatal intensive care unit. Participants were admitted neonates during 50 weeks. Medication errors and potential or preventable ADEs were detected by a daily structured audit of each subject's medical record, with assignment of an event as a preventable ADE made by blinded assessors. The generalized estimating equation method was used in modeling the targeted, preventable ADE rate with covariates.
Results
A total of 92 398 medication doses were administered to 958 subjects. The generalized estimating equation method yielded a relative risk of preventable ADE when the system was implemented of 0.53 (95% confidence limits 0.29 to 0.91, P = .04), adjusted for log10doses of medication/subject/day, a significant predictive covariate (P < .001), as well as for birth weight, sex, Caucasian race, birth cohort number, and nursing hours/subject/day.
Conclusion
The BCMA system reduced the risk of targeted, preventable ADEs by 47%, controlling for the number of medication doses/subject/day, an important risk exposure.
Abbreviations: ADE, Adverse drug event, BCMA, Barcode medication administration, CPOE, Computer prescriber order entry, GEE, Generalized estimating equation, MAR, Medication administration record, NICU, Neonatal intensive care unit, SD, Standard deviation, UIHC, University of Iowa Hospitals and Clinics
To access this article, please choose from the options below
Funded by grants from the American Society of Health-System Pharmacists Research and Education Foundation and the University of Iowa Pharmaceutical Enterprise. The American Society of Health-System Pharmacists Research and Education Foundation had no role in study design, collection, analysis or interpretation of the data, the writing of the report, nor the decision to submit the manuscript for publication. Paul Abramowitz is currently an officer of the American Society of Health-System Pharmacists Research and Education Foundation. The other authors have no actual or perceived conflicts of interest.
PII: S0022-3476(08)00705-1
doi:10.1016/j.jpeds.2008.08.025
© 2009 Mosby, Inc. All rights reserved.
